Neurocrine Biosciences Market Sentiment

Neurocrine Biosciences Inc

NBIXNASDAQ

$146.10

-0.28-0.19%

Últ. Act.: Oct 30, 5:09 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivo FinanzasSentimientoPropiedad Comparar Opciones Informe de acciones

Ganancias: Los beneficios de Q3 2026 mañana en lun nov 2nd después del cierre del mercado

Conferencia telefónica: Conferencia telefónica programada para mañana a las 4:30 p. m.

Haz clic para ver el webcast

Neurocrine Biosciences Market Sentiment

Market sentiment signals for Neurocrine Biosciences (NBIX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 8.3% short float

Options Flow▲ 0.23 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

25 analysts

Options Flow (P/C)

0.23

More calls — Bullish

273 calls · 63 puts

Avg Consensus PT

$201

+40.8%

Highest Price Target

$253

+76.9%

Citigroup

Lowest Price Target

$150

+4.9%

BMO Capital

Short Interest

8.3%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 16, 2026	Needham	Ami Fadia—	+42.7%	$204 → $204	Maintained	Buy
Oct 12, 2026	BMO Capital	Evan Seigerman—	+4.9%	$164 → $150	Maintained	Market Perform
Oct 6, 2026	Guggenheim	Delma Caiati—	+44.8%	$207	Assumes	Buy
Sep 29, 2026	UBS	Ashwani Verma—	+49.7%	$231 → $214	Maintained	Buy
Sep 11, 2026	Morgan Stanley	Jeffrey Hung—	+28.0%	$182 → $183	Maintained	Equal-Weight
Sep 8, 2026	RBC Capital	Brian Abrahams—	+38.5%	$198 → $198	Maintained	Outperform
Sep 3, 2026	Citigroup	Yigal Nochomovitz—	+76.9%	$249 → $253	Maintained	Buy
Aug 13, 2026	Morgan Stanley	Jeffrey Hung—	+27.3%	$196 → $182	Maintained	Equal-Weight
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni—	+46.9%	$200 → $210	Maintained	Buy
Aug 3, 2026	Truist Securities	Danielle Brill—	+49.0%	$200 → $213	Maintained	Buy
Aug 3, 2026	Wedbush	Laura Chico—	+35.7%	$185 → $194	Maintained	Outperform
Jul 31, 2026	Citigroup	Yigal Nochomovitz—	+74.1%	$246 → $249	Maintained	Buy
Jul 31, 2026	RBC Capital	Brian Abrahams—	+38.5%	$195 → $198	Maintained	Outperform
Jul 31, 2026	Morgan Stanley	Jeffrey Hung—	+37.1%	$193 → $196	Maintained	Equal-Weight
Jul 31, 2026	TD Cowen	Phil Nadeau—	+53.8%	$200 → $220	Maintained	Buy
Jul 31, 2026	Piper Sandler	David Amsellem—	+46.9%	$207 → $210	Maintained	Overweight
Jul 31, 2026	Cantor Fitzgerald	Josh Schimmer—	+50.3%	$210 → $215	Maintained	Overweight
Jul 31, 2026	Guggenheim	Yatin Suneja—	+55.2%	$200 → $222	Maintained	Buy
Jul 31, 2026	Stifel	Paul Matteis—	+50.3%	$188 → $215	Maintained	Buy
Jul 31, 2026	Needham	Ami Fadia—	+42.7%	$200 → $204	Maintained	Buy
Jul 21, 2026	Guggenheim	Brad Canino—	+39.9%	$175 → $200	Maintained	Buy
Jul 17, 2026	Wells Fargo	Mohit Bansal—	+39.9%	$175 → $200	Maintained	Overweight
Jul 13, 2026	Truist Securities	Danielle Brill—	+39.9%	$155 → $200	Maintained	Buy
Jul 13, 2026	BMO Capital	Evan Seigerman—	+18.9%	$144 → $170	Maintained	Market Perform
Jul 7, 2026	RBC Capital	Brian Abrahams—	+36.4%	$183 → $195	Maintained	Outperform